Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VDC vs XBI: how they differ
VDC and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Consumer Staples Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VDC and XBI hold 0% of their money in the same securities at the same weight.
| Only in VDC | Only in XBI |
|---|---|
| Walmart Inc 14.76% | Apogee Therapeutics Inc 1.49% |
| Costco Wholesale Corp 12.04% | Moderna Inc 1.41% |
| Procter & Gamble Co/The 9.27% | Twist Bioscience Corp 1.41% |
| Coca-Cola Co/The 8.72% | Oruka Therapeutics Inc 1.38% |
| Philip Morris International Inc 4.66% | Kymera Therapeutics Inc 1.36% |
| PepsiCo Inc 4.30% | Viking Therapeutics Inc 1.31% |
| Altria Group Inc 3.91% | Praxis Precision Medicines Inc 1.29% |
| Mondelez International Inc 2.69% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| VDC Vanguard Consumer Staples Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Consumer Staples | SPDR S&P Biotech |
| Total return, 1 year | +4.6% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −12.9 pts | +46.5 pts |
| Expense ratio | 0.09% | 0.35% |
| Already in the S&P 500 | 86.6% | 8.5% |
| Holdings | 103 | 150 |
VDC in plain words
VDC is an index equity fund tracking the Consumer Staples. Over the year to Sep 11, 2026 it returned +4.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.09% a year. By its holdings filed for May 31, 2026, 87% of the fund by weight is stocks the S&P 500 also holds, across 103 positions, with the top ten at 65.0%. It sat 6.8% below its high of Feb 27, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VDC or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VDC returned +4.6% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VDC or XBI?
- VDC charges 0.09% a year and XBI charges 0.35%, so VDC is cheaper. Fees come from each fund's prospectus.
- How much do VDC and XBI overlap with the S&P 500?
- By their latest filed holdings, 87% of VDC and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VDC against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VDC-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources